Malievskaia E
Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, United Kingdom.
PreprintPsilocybin
Distinct response of resting-state brain networks to psilocybin in autism
ArticlePsilocybin
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
ArticlePsilocybin
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
ArticlePsilocybin
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
ArticlePsilocybin
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.
ArticlePsilocybin
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
ArticlePsilocybin
The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin.
ArticlePsilocybin
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary.
ArticlePsilocybin
Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression
ArticlePsilocybin
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
ArticlePsilocybin
Unblinding and demand characteristics in the treatment of depression.
ArticlePsilocybin
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
ArticlePsilocybin